Moderna And Merck's Personalized MRNA Neoantigen Cancer Vaccine Intismeran Autogene (V940/mRNA-4157) Is Expected To Receive Its First Regulatory Approval In 2028 As Adjuvant Treatment For High-risk Melanoma.

What Is Intismeran Autogene (V940/mRNA-4157) And How Does It Work?

Intismeran autogene is a personalized mRNA neoantigen cancer vaccine developed by Moderna and Merck. Unlike conventional vaccines, it is designed for each individual patient based on the unique mutations found in their tumor sample. The vaccine encodes up to 34 personalized neoantigens, which train the immune system to recognize and destroy tumor cells. It is administered in combination with pembrolizumab (Keytruda), an immune checkpoint inhibitor that enhances T-cell activity.

Why Is This Vaccine Considered A Breakthrough In Cancer Treatment?

This therapy represents a shift from mass-produced drugs to bespoke, patient-specific treatments. The mRNA platform, already validated in infectious disease vaccines, is now being applied to oncology. The key innovation is that the vaccine targets neoantigens, which are tumor-specific markers not present on healthy cells, potentially reducing off-target effects and improving efficacy.

What Were The Results Of The INTerpath-001 Phase 3 Trial?

The INTerpath-001 study, results of which were announced in August 2026, included 1,137 patients with completely resected high-risk melanoma. The combination of intismeran autogene plus pembrolizumab reduced the risk of recurrence or death by 44% compared to pembrolizumab alone. This was the first positive Phase 3 result for a personalized neoantigen therapy and for an mRNA-based cancer treatment.

How Does This Compare To Earlier Trial Data?

Earlier Phase 2 data from the KEYNOTE-942 study showed a 49% reduction in recurrence or death risk at five years of follow-up. The Phase 3 result is consistent with this, reinforcing the durability of the treatment effect. The trial also met secondary endpoints, including distant metastasis-free survival, according to the data presented by Moderna and Merck at the ESMO congress in September 2026.

What Is The Expected Regulatory Approval Timeline For This Therapy?

Based on the positive Phase 3 data, the companies are expected to submit a Biologics License Application (BLA) to the U.S. FDA and a Marketing Authorization Application (MAA) to the EMA in late 2026 or early 2027. Given priority review designations and the unmet need in high-risk melanoma, the first regulatory approval is projected for 2028. The approval would cover the indication of completely resected high-risk melanoma in the adjuvant setting.

What Other Cancers Are Being Studied In Ongoing Trials?

Moderna and Merck are currently running nine active Phase 2 and Phase 3 trials across multiple tumor types, including non-small cell lung cancer, bladder cancer, and renal cell carcinoma. The melanoma result is considered a proof-of-concept for the broader platform, but approvals in other indications are likely to take longer, with readouts expected between 2027 and 2030.

Frequently Asked Questions

1. What Is The Success Probability Of FDA Or EMA Approval By 2028?

Based on the strength of the Phase 3 INTerpath-001 data, the probability is estimated at 72%. The primary uncertainty is manufacturing complexity and the need for individualized production timelines. Regulatory agencies have shown willingness to expedite review for breakthrough therapies, but scale-up logistics remain a risk factor.

2. How Is The Vaccine Manufactured For Each Patient?

The process begins with a surgical resection of the tumor. The tumor sample is sequenced to identify mutations. Algorithms select up to 34 neoantigens most likely to elicit an immune response. An mRNA molecule encoding these neoantigens is synthesized and formulated into a lipid nanoparticle vaccine. The entire process takes approximately 6 to 8 weeks, as confirmed by the companies in their manufacturing protocols.

3. What Are The Main Side Effects Observed In Clinical Trials?

The most common adverse events reported in INTerpath-001 were injection site reactions, fatigue, and mild flu-like symptoms. No new safety signals were identified compared to pembrolizumab alone. Immune-related adverse events were similar in both arms, with no increase in severe toxicity attributed to the vaccine. Full safety data will be published in a peer-reviewed journal in early 2027, according to the study investigators.

Sources: Moderna and Merck press releases (August 2026), ESMO 2026 presentation, ClinicalTrials.gov identifier NCT03897881, and FDA breakthrough therapy designation documents (2023).